A Phase 2/3 interventional study of Blinatumomab (Group A) and Venetoclax (nonRand Group) in Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic and B Cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 27 sites in 2 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 4th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 32 of the 38 other live ones, and was the 51st registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, France, Israel and 3 more countries
Ages 1–30
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Liping Dou · Sites in China
Ages 18–70
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 41 · Phase 3 14 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 67 across the 61 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 61 have an industry lead sponsor. The 10 most frequent:
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
28 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Institute of Hematology & Blood Diseases Hospital, China: 21 open now, 22 under way, 4 of them phase 3. Of 5 finished, 0 (0%) have results posted.
Among the 28 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Institute of Hematology & Blood Diseases Hospital, China, this one is the 2nd largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 17 of the 21 other live ones, and was the 18th registered.
Institute of Hematology & Blood Diseases Hospital, China’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 2015.
11 of the studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT04722848Phase 3Gruppo Italiano Malattie EMatologiche dell'AdultoSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | 2027-09 |
| NCT06387121Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | 2026-12-01 |
| NCT03114865Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsA Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | 2026-12-30 |
| NCT05519579Northside Hospital, Inc.Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Among Institute of Hematology & Blood Diseases Hospital, China’s 28 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
This tab as a report to print or save as PDF → With an account.
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and high- risk B-cell childhood acute lymphoblastic leukaemia (I/HR-B-ALL), while decreasing adverse reactions and transplantation rates. This trial primarily aims to explore:
The study shown above will lead to the following revisions to the CCCG-ALL2025 I/HR-B-ALL plan, which will be based on the CCCG-ALL2020 plan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After PVDL+CAT induction remission phase, patients randomized to Group A will be subjected to consolidation phase with continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX)
Drug: Blinatumomab (Group A)
After PVDL+CAT induction remission phase, patients randomized to Group B will be subjected to consolidation phase with two 14-day cycles of blinatumomab, alternating with 3 cycles of high-dose methotrexate (HDMTX).
Drug: Blinatumomab (Group B)
Patients who will not be subjected to blinatomomab randomization, will received PVDL + Venetoclax + mini-hyperCVD as induction phase , subsequently receiving CAT as early intensification.
Drug: Venetoclax (nonRand Group)
For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
Also known as: high-dose methotrexate
For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy
Also known as: cyclophosphamide, vincristine, dexamethasone
For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
Also known as: high-dose methotrexate
To investigate if Group B[2*(14-day blinatumomab + HDMTX*2)] can result in noninferior event-free survival (EFS) compared to Group A [28-day blinatumomab + HDMTX*4
* The randomization is stratified by hospitals and status of flow-cytometry MRD (positive or negative) immediately prior to the blinatumomab-HDMTX treatment. * Kaplan-Meier (KM) estimates of each EFS function will be computed along with standard error by the default procedure in R. To test noninferiority the investigators consider a noninferiority margin of 0.04 for 5-year EFS as clinically meaningful. * Assume the EFS in the control group (Arm A) to be the same as the provisional I/HR in the CCCG-ALL2020 trial (preliminary data above), with the 1-year and 3-year EFS possibly 0.837 and 0.768 respectively. A simulation study with 10,000 rounds shows that by randomizing 1800 patients and 1.5 years of follow up, the above decision rule of declaring noninferiority has well controlled probabilities of false positive and false negative errors.
Time frame: Based on the above analysis in this study the investigators will randomize 1800 patients. The analysis will start1.5 years after the last patient is randomized. The expected study duration is approximately 6.5 years.
Event-free survival (EFS) in the two randomized arms [2*(14-day blinatumomab + HDMTX*2)] and [28-day blinatumomab + HDMTX*4], in contrast to historical regimens.
EFS functions will be estimated using the Kaplan-Meier estimator of survival functions along with 95% confidence interval at 5 year. Standard error will be estimated using the default procedure in R. Follow up of the historical comparison cohort (CCCG-ALL-2020 and 2015) will continue during the course of the current trial. Comparisons of EFS will be performed using two-sided log-rank test. Multivariable regression modeling including trial (CCCGALL-2025 vs. 2020 or 2015) and other known prognostic factors as main effects may also be performed, using the Cox models.
Time frame: Up to 5 years for every enrolled case
Cumulative incidence of relapse (CIR) in the two randomized arms [2*(14-day blinatumomab + HDMTX*2)] and [28-day blinatumomab + HDMTX*4], in contrast to historical regimen.
CIR functions of relapse will be estimated by the Kalbafleisch-Prentice method. Follow up of the historical comparison cohort (CCCG-ALL-2020 and 2015) will continue during the course of the current trial. Comparisons of CIR will be performed by Gray's test. Multivariable regression modeling including trial (CCCGALL-2025 vs. 2020 or 2015) and other known prognostic factors as main effects may also be performed, using the Fine-Gray models.
Time frame: Up to 5 years for every enrolled case
Overall survival (OS) in the two randomized arms [2*(14-day blinatumomab + HDMTX*2)] and [28-day blinatumomab + HDMTX*4], in contrast to historical regimens.
OS functions will be estimated using the Kaplan-Meier estimator of survival functions along with 95% confidence interval at 5 year. Standard error will be estimated using the default procedure in R. Follow up of the historical comparison cohort (CCCG-ALL-2020 and 2015) will continue during the course of the current trial. Comparisons of OS will be performed using two-sided log-rank test. Multivariable regression modeling including trial (CCCGALL-2025 vs. 2020 or 2015) and other known prognostic factors as main effects may also be performed, using the Cox models.
Time frame: Up to 5 years for every enrolled case
EFS in patients who receive 6 alternated venetoclax/Daunorubincin courses of interim continuation therapy.
EFS functions will be estimated using the Kaplan-Meier estimator of survival functions along with 95% confidence interval at 5 year. Standard error will be estimated using the default procedure in R. Follow up of the historical comparison cohort (CCCG-ALL-2020 and 2015) will continue during the course of the current trial. Comparisons of EFS will be performed using two-sided log-rank test.Multivariable regression modeling including trial (CCCGALL-2025 vs. 2020 or 2015) and other known prognostic factors as main effects may also be performed, using the Cox models.
Time frame: Up to 5 years for every enrolled case
CIR in patients who receive 6 alternated venetoclax/Daunorubincin courses of interim continuation therapy.
CIR functions of relapse will be estimated by the Kalbafleisch-Prentice method. Follow up of the historical comparison cohort (CCCG-ALL-2020 and 2015) will continue during the course of the current trial. Comparisons of CIR will be performed by Gray's test. Multivariable regression modeling including trial (CCCGALL-2025 vs. 2020 or 2015) and other known prognostic factors as main effects may also be performed, using the Fine-Gray models.
Time frame: Up to five years for every enrolled case
OS in patients who receive 6 alternated venetoclax/Daunorubincin courses of interim continuation therapy.
OS will be estimated using the Kaplan-Meier estimator of survival functions along with 95% confidence interval at 5 year. Standard error will be estimated using the default procedure in R. Follow up of the historical comparison cohort (CCCG-ALL-2020 and 2015) will continue during the course of the current trial. Comparisons of OS will be performed using two-sided log-rank test. Multivariable regression modeling including trial (CCCGALL-2025 vs. 2020 or 2015) and other known prognostic factors as main effects may also be performed, using the Cox models.
Time frame: Up to five years for every enrolled case
To compare grade 3 or higher adverse effects (AEs; CTCAE v5.0) and estimate their cumulative incidences
Proportions of grade-3 or higher AEs in each treatment phase will be estimated by the sample proportions along with exact 95% confidence intervals. Cumulative incidences of various grade-3 or higher AEs throughout therapy will be estimated by the Kalbafleisch-Prentice method; death, relapse and other events rendering off therapy before completion are regarded as competing risks.
Time frame: Up to 30 days after last dose of study treatment
measurable residual diseases (MRD) positivity by next-generation sequencing of immunoglobulin gene(IgH NGS) after blinatumomab-HDMTX therapy between the two randomized arms [2*(14-day blinatumomab + HDMTX*2)] and [28-day blinatumomab + HDMTX*4].
Proportions of patients with positive IgH NGS MRD in each arm will be estimated by the sample proportion along with the 95% confidence interval. The NGS MRD positive proportions will be compared by the two-sample z test. If the NGS MRD positive proportions are very low in one or both arms, Fisher's exact test will be applied.
Time frame: Up to five years
Cellular immune-status prior to Blinatumomab-HDMTX consolidation therapy
Descriptive statistics on T lymphocytes functions (exhaustion, activation, TCR diversity, etc.) including correlation coefficients (Pearson's or Spearman's) and regression modeling including possibly longitudinal data models will be applied as appropriate to analyze the biological associations.
Time frame: At the end of induction
Cellular immune functions after blinatumomab-HDMTX consolidation
Descriptive statistics on T lymphocytes functions (exhaustion, activation, TCR diversity, etc.).including correlation coefficients (Pearson's or Spearman's) and regression modeling including possibly longitudinal data models will be applied as appropriate to analyze the biological associations.
Time frame: Up to 2 years
Plan to share: Yes — Demographic Data: Age, sex, and other relevant baseline characteristics. Treatment Information: Data on interventions received by participants, including dosage, treatment cycles, and duration. Outcome Measures: Detailed information on primary and secondary outcome measures, such as response rates, survival rates, adverse events, and any the pre-specified endpoints. Adverse Events: Data on all reported adverse events, including severity, duration, and outcome. Laboratory Data: Results from laboratory tests, such as blood counts, biochemical markers, or molecular analysis. Medical History: Pre-existing conditions, comorbidities, and prior treatments or interventions. Vital Signs: relevant physiological data. Efficacy and Safety Data: Any data relating to the efficacy (e.g., event-free survival) and safety (e.g., adverse effects) of the treatment.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: IPD will be made available upon publication of the primary trial results or after trial completion, whichever occurs first, starting on 2030, and will remain accessible for 5 years.
Access criteria: Researchers, healthcare professionals who meet the criteria for access (e.g., academic researchers conducting secondary analyses or regulatory bodies reviewing safety data) will be able to request access to de-identified IPD and supporting information. Access will be facilitated through clinical trials.gov/emailing to PI, where users can submit a request and provide a research proposal. Data access will be granted after a formal review and approval process, subject to compliance with the data-sharing agreement and confidentiality terms.
Data sharing details ↗ · cccg.nipher.com
Started Jan 2025 (actual). Primary completion is estimated for Dec 2029, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Blinatumomab · Venetoclax
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Institute of Hematology & Blood Diseases Hospital, China →